BIOBio-Rad Laboratories Inc. - Ordinary Shares - Class A
Earnings Recap
• Reported GAAP EPS of $26.69 up 204.38% YoY • Reported revenue of $693.2M up 3.85% YoY • Bio-Rad expects non-GAAP currency neutral revenue growth of approximately 0.5% to 1.5% and an estimated non-GAAP operating margin of 12.0% to 12.5% for the full-year 2026.
Bullish
Bio-Rad achieved a significant net income turnaround to $720.0 million in Q4 2025, driven by investment fair value changes. Clinical Diagnostics sales grew 8.4%, and the company expanded its ddPCR product portfolio and global product access.
Bearish
Bio-Rad faced continued pressure on academic research and biotech funding, leading to a 2.6% decline in Life Science segment sales. Gross and operating margins fell below expectations, and the company recognized a $172.8 million impairment of purchased intangibles.